Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.25.
Forward PE Ratio (15.25) = Close Price ($50.37) / Consensus Forward EPS ($3.30)
FORWARD PE RATIO
15.25
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-23.42%
vs the sector median at left
Boston Scientific Corporation
Market Cap
$74.87B
Forward PE Ratio
15.25
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Boston Scientific Corporation (BSX) | $74.87B | 15.25 |
| Cigna Corporation (CI)vs › | $73.33B | 9.10 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $85.92B | 15.38 |
| Elevance Health Inc. (ELV)vs › | $86.86B | 14.75 |
| Cencora, Inc. (COR)vs › | $61.88B | 17.79 |
| Moderna, Inc. (MRNA)vs › | $57.59B | N/A |
| HCA Healthcare, Inc. (HCA)vs › | $92.92B | 14.54 |
| Cardinal Health, Inc. (CAH)vs › | $53.75B | 21.30 |
| Becton, Dickinson and Company (BDX)vs › | $52.90B | 15.15 |
| Edwards Lifesciences Corporation (EW)vs › | $51.70B | 29.92 |
Trailing P/E
20.5
reported TTM EPS
Forward P/E
15.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.30 implies +34.1% EPS growth vs the reported trailing $2.46.
At today's $50.37 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.30 | $3.28 – $3.36 | 15 | 15.2x |
| 2027-12-31 | $3.42 | $3.32 – $3.71 | 16 | 14.7x |
| 2028-12-31 | $3.77 | $3.61 – $4.06 | 7 | 13.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
